A recent study reveals that Canada is unlikely to meet the original World Health Organization (WHO) goal of eliminating the Hepatitis C virus (HCV) by 2030. Furthermore, the study highlights that Canada’s progress in this regard lags behind that of other developed nations. ()

HCV is an infection that poses a major public health threat that affects an estimated 250,000 Canadians – despite having a highly effective medication.

When gone unscreened, HCV is a highly debilitating infection that causes liver failure and could lead to death. Due to its asymptomatic nature, it is also known as a silent killer to those infected with the virus. The infection typically spreads through contact with an infected person’s blood, most commonly through needle sharing.

“There is no model in Canada to track the elimination process,” said Dr. William W.L. Wong, associate professor at Waterloo’s School of Pharmacy, which offers the most innovative pharmacy curriculum in North America by integrating biomedical and pharmacy science with clinical, behavioral and social sciences to emphasize patient-focused care.

Addressing Hepatitis C Challenges

Wong, the study’s lead author and newly appointed 2024 Applied Public Health Chair, added: “We need to screen for the disease earlier and encourage harm-reduction strategies be put in place. If patients do not change high-risk behaviors, such as sharing needles, HCV re-infection can be high even after they were cured the first time.”

Wong used a novel mathematical modelling system to help determine how Canada’s progress would fare to eradicate HCV. Based on Wong’s model, reaching the WHO goals by 2030 will be impossible if the current status quo treatment and screening policies don’t change.

“Picture a game, such as The Sims, where you build a dynamic population,” Wong said. “Similar to the game, we simulated Ontario’s population, including those with HCV. We looked at how the disease is transmitted and how it moves around the population with different risk activities triggered.”

The researchers suggest that policymakers should consider harm-reduction strategies such as implementing clean needle distributions, reducing the sharing of drug use equipment and other high-risk exposures.

The researchers will be integrating future work with other sexually transmitted and blood-borne infections, including hepatitis B virus, human papillomavirus and HIV.

Reference:

1. Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries – (https://journals.lww.com/hep/fulltext/9900/feasibility_of_hepatitis_c_elimination_by.748.aspx)

Source-Eurekalert